News | Antiplatelet and Anticoagulation Therapies | February 19, 2018

Xarelto Reduces Ischemic Stroke for Coronary and Peripheral Artery Disease Patients

Late-breaking analysis also found high-risk patients taking Xarelto plus aspirin had largest reductions in stroke

Xarelto Reduces Ischemic Stroke for Coronary and Peripheral Artery Disease Patients

February 19, 2018 — A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International Stroke Conference (ISC), showing that people with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) taking Xarelto (rivaroxaban) had fewer ischemic strokes compared to those taking aspirin alone. This analysis, which specifically examined patients from COMPASS who experienced a stroke, also found high-risk patients taking Xarelto plus aspirin had the largest reductions in stroke.

CAD and PAD affect 16.5 million and 10 million Americans, respectively, and can serve as red-flag warnings that a more serious cardiovascular (CV) event, like heart attack or stroke, may occur at any time. In fact, each year, approximately 5 percent of people with CAD/PAD will experience a CV event, despite use of preventative medicines.

Xarelto (rivaroxaban) is the only Factor Xa inhibitor to be investigated in CAD and PAD, according to the company. Of note, COMPASS was stopped approximately one year ahead of schedule due to efficacy, and primary results were recently published in The New England Journal of Medicine and presented at the 2017 ESC Congress. In December 2017, Janssen submitted a supplemental New Drug Application (sNDA) to the FDA for two new Xarelto vascular indications based on COMPASS: reducing the risk of major CV events such as CV death, heart attack or stroke in patients with chronic CAD and/or PAD; and for reducing the risk of acute limb ischemia in patients with PAD.

For more information: www.janssen.com

 

Related Content

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images #ACC #ACC21 #ACC2021

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images

News | Antiplatelet and Anticoagulation Therapies | May 15, 2021
May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in pat
A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

News | Antiplatelet and Anticoagulation Therapies | April 28, 2021
April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term,...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Additional figure included in the JACC article.

Feature | Antiplatelet and Anticoagulation Therapies | March 22, 2021 | By Dave Fornell, Editor
A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal a
Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.
News | Antiplatelet and Anticoagulation Therapies | September 02, 2020
September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce
Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to p